Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 1.5%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 1.3% as of midday close [1] - The recent revision of the Hang Seng Hong Kong Stock Connect Innovative Drug Index explicitly excludes CXO companies, focusing solely on core innovative drug companies, making it one of the first indices with a "purity" of 100% for innovative drugs tracked by ETFs [1] Group 2 - The CSI 300 Pharmaceutical and Health Index focuses on leading A-share companies in the pharmaceutical sector, covering chemical pharmaceuticals, medical services, and medical devices [4] - Since its inception in December 2007, the CSI 300 Pharmaceutical and Health Index has a valuation percentile of 30.2 times [4]